{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:45:45Z","timestamp":1790711145176,"version":"4.1.0"},"reference-count":28,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To identify predictors of body weight (BW) reduction of \u226515% with tirzepatide treatment and to describe associated clinical parameters of participants with type 2 diabetes (T2D) who achieved different categorical measures of BW reduction (&amp;lt;5%, \u22655 to &amp;lt;10%, \u226510 to &amp;lt;15%, and \u226515%)\u00a0across four studies from the phase 3 SURPASS clinical trial program for T2D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>The multivariate model for predictor of a BW reduction of \u226515% included age, sex, race, BW, HbA1c, tirzepatide dose and baseline metformin use, fasting serum glucose, and non-HDL cholesterol. Baseline characteristics and change from baseline to week 40\/42 for efficacy parameters were described and analyzed in treatment-adherent participants (\u226575% doses administered and on treatment at week 40\/42) receiving once weekly tirzepatide (5 mg, 10 mg, or 15 mg) (N = 3,188).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Factors significantly associated with achieving a BW reduction of \u226515% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, and lower HbA1c, fasting serum glucose, and non-HDL cholesterol at baseline. With higher categorical BW reduction, there were greater reductions in HbA1c, triglycerides, ALT, waist circumference, and blood pressure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Baseline factors associated with a higher likelihood of achieving a BW reduction of \u226515% with tirzepatide were higher tirzepatide doses, female sex, White or Asian race, younger age, metformin background therapy, better glycemic status, and lower non-HDL cholesterol. With greater BW reduction, participants with T2D achieved larger improvements in glycemia and cardiometabolic risk parameters. These findings help inform which people with T2D are most likely to achieve greater BW reduction with improved cardiometabolic risk factors with tirzepatide.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc23-1135","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T19:52:15Z","timestamp":1697140335000},"page":"2292-2299","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":52,"title":["Predictors of \u226515% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1\u20134"],"prefix":"10.2337","volume":"46","author":[{"given":"Maciej T.","family":"Ma\u0142ecki","sequence":"first","affiliation":[{"name":"1Department of Metabolic Diseases, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Batterham","sequence":"additional","affiliation":[{"name":"2University College London, London, U.K."},{"name":"3Eli Lilly and Company, Basingstoke, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"4British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Levine","sequence":"additional","affiliation":[{"name":"5Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"6Lilly Spain, Alcobendas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bergman","sequence":"additional","affiliation":[{"name":"5Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"7TechData Service Company, King of Prussia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Ghimpeteanu","sequence":"additional","affiliation":[{"name":"8Eli Lilly Romania, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-0207","authenticated-orcid":false,"given":"Clare J.","family":"Lee","sequence":"additional","affiliation":[{"name":"5Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"2023112719542032700_B1","doi-asserted-by":"crossref","first-page":"333S","DOI":"10.1093\/jn\/131.2.333S","article-title":"Symposium: nutritional and metabolic diversity: understanding the basis of biologic variance in the obesity\/diabetes\/cardiovascular disease connection. Introduction","volume":"131","author":"Tobin","year":"2001","journal-title":"J Nutr"},{"key":"2023112719542032700_B2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023112719542032700_B3","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2023112719542032700_B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2023112719542032700_B5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"2023112719542032700_B6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2023112719542032700_B7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"2023112719542032700_B8","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"2023112719542032700_B9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"2023112719542032700_B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11883-011-0224-x","article-title":"The role of non-HDL cholesterol in risk stratification for coronary artery disease","volume":"14","author":"Rana","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"2023112719542032700_B11","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"2023112719542032700_B12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"2023112719542032700_B13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"2023112719542032700_B14","article-title":"Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?","author":"Sattar","journal-title":"Cardiovasc Res"},{"key":"2023112719542032700_B15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"key":"2023112719542032700_B16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","article-title":"Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes","volume":"6","author":"Lee","year":"1998","journal-title":"Obes Res"},{"key":"2023112719542032700_B17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s001250051172","article-title":"Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus","volume":"42","author":"M\u00e4kimattila","year":"1999","journal-title":"Diabetologia"},{"key":"2023112719542032700_B18","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1007\/s11695-020-04877-7","article-title":"Pre-operative predictors of weight loss and weight regain following Roux-en-Y gastric bypass surgery: a prospective human study","volume":"30","author":"Aliakbarian","year":"2020","journal-title":"Obes Surg"},{"key":"2023112719542032700_B19","doi-asserted-by":"crossref","first-page":"154388","DOI":"10.1016\/j.metabol.2020.154388","article-title":"Factors affecting weight loss variability in obesity","volume":"113","author":"Dent","year":"2020","journal-title":"Metabolism"},{"key":"2023112719542032700_B20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13293-018-0189-3","article-title":"Sex differences in body composition and association with cardiometabolic risk","volume":"9","author":"Schorr","year":"2018","journal-title":"Biol Sex Differ"},{"key":"2023112719542032700_B21","doi-asserted-by":"crossref","first-page":"dgz072","DOI":"10.1210\/clinem\/dgz072","article-title":"Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials","volume":"105","author":"DeSouza","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023112719542032700_B22","doi-asserted-by":"crossref","first-page":"e190029","DOI":"10.1001\/jamasurg.2019.0029","article-title":"Association of race with bariatric surgery outcomes","volume":"154","author":"Wood","year":"2019","journal-title":"JAMA Surg"},{"key":"2023112719542032700_B23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.amjsurg.2021.09.011","article-title":"Racial disparities in bariatric surgery postoperative weight loss and patient satisfaction","volume":"223","author":"Samaan","year":"2022","journal-title":"Am J Surg"},{"key":"2023112719542032700_B24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/0884533614568154","article-title":"Preoperative predictors of weight loss at 4 years following bariatric surgery","volume":"30","author":"Parri","year":"2015","journal-title":"Nutr Clin Pract"},{"key":"2023112719542032700_B25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40519-017-0425-6","article-title":"Patient predictors of weight loss following a behavioral weight management intervention among US Veterans with severe obesity","volume":"23","author":"Funk","year":"2018","journal-title":"Eat Weight Disord"},{"key":"2023112719542032700_B26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/dc07-1463","article-title":"Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects","volume":"31","author":"Kotronen","year":"2008","journal-title":"Diabetes Care"},{"key":"2023112719542032700_B27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1477-7525-11-165","article-title":"Predictors of weight loss after an intensive lifestyle intervention program in obese patients: a 1-year prospective cohort study","volume":"11","author":"Karlsen","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2023112719542032700_B28","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","author":"Patel","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/12\/2292\/739536\/dc231135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/12\/2292\/739536\/dc231135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T19:55:21Z","timestamp":1701114921000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/12\/2292\/153724\/Predictors-of-15-Weight-Reduction-and-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1135","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}